GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased ...

In older patients with cancer and type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1RA) use was associated with lower all-cause mortality compared with dipeptidyl peptidase-4 inhibitor ...

CHICAGO — Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in body weight compared with placebo ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have led to hospitalisations and even deaths.

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find out why NVO stock is a buy.

Findings of study demonstrating the effectiveness of combining bimagrumab – a drug designed to combat muscle loss – with a common GLP-1 receptor agonist (RA), semaglutide, were presented ...

Registered dietitian lost 60 pounds with GLP-1 weight loss drug Wegovy. She shares foods to avoid and prioritize to minimize side effects and muscle loss.

Findings also show improved persistence with high-potency, obesity-approved GLP-1 products In addition to persistence and adherence insights, the Year-3 study found 38% of individuals switched GLP ...